MAB3303
Anti-Collagen Type VI Antibody, clone VI-26
clone VI-26, Chemicon®, from mouse
別名:
Anti-BTHLM1, Anti-OPLL, Anti-UCHMD1
製品名
Anti-Collagen Type VI Antibody, clone VI-26, clone VI-26, Chemicon®, from mouse
biological source
mouse
conjugate
unconjugated
antibody form
purified immunoglobulin
antibody product type
primary antibodies
clone
VI-26, monoclonal
species reactivity
human, rabbit
should not react with
rat
manufacturer/tradename
Chemicon®
availability
not available in Japan
technique(s)
ELISA: suitable
immunohistochemistry: suitable (paraffin)
isotype
IgG1κ
NCBI accession no.
UniProt accession no.
shipped in
dry ice
target post-translational modification
unmodified
Quality Level
Gene Information
human ... COL6A1(1291)
Analysis Note
Control
Testis, connective tissue
Testis, connective tissue
Application
Anti-Collagen Type VI Antibody, clone VI-26 detects level of Collagen Type VI & has been published & validated for use in ELISA, IH(P).
Immunohistochemistry on acetone fixed paraffin-embedded tissues. Formalin fixation is not recommended. Antigen recovery is treatment with 0.04% trypsin in 0.01M CaCl(2) 0.05M Tris-HCL pH 7.6, 37°C for 10 minutes before the non-specific peroxidase block.
EIA
Optimal working dilutions must be determined by end user.
EIA
Optimal working dilutions must be determined by end user.
Research Category
Cell Structure
Cell Structure
Research Sub Category
ECM Proteins
ECM Proteins
Biochem/physiol Actions
Specifically reacts with the hCL(VI). This is a purified mouse monoclonal antibody to human type VI collagen. VI-26 does not react with denatured or reduced type VI collagen, although this antibody does recognize the the triple helix consisting of alpha1(VI), alpha 2(VI) alpha3(gamma). The epitope has not been mapped and the monoclonal is know not to react with collagens I, II, III, IV or V in native assays.
Disclaimer
Unless otherwise stated in our catalog or other company documentation accompanying the product(s), our products are intended for research use only and are not to be used for any other purpose, which includes but is not limited to, unauthorized commercial uses, in vitro diagnostic uses, ex vivo or in vivo therapeutic uses or any type of consumption or application to humans or animals.
Other Notes
Concentration: Please refer to the Certificate of Analysis for the lot-specific concentration.
Physical form
Format: Purified
Liquid in 0.1 M sodium phosphate buffer, pH 7.0, containing 2% protease-free bovine Serum albumin.
Protein A purified
Preparation Note
Maintain for 1 year at -20°C from date of shipment. Aliquot to avoid repeated freezing and thawing. For maximum recovery of product, centrifuge the original vial after thawing and prior to removing the cap.
Legal Information
CHEMICON is a registered trademark of Merck KGaA, Darmstadt, Germany
適切な製品が見つかりませんか。
製品選択ツール.をお試しください
保管分類
12 - Non Combustible Liquids
wgk
WGK 2
flash_point_f
Not applicable
flash_point_c
Not applicable
試験成績書（COA）
製品のロット番号・バッチ番号を入力して、試験成績書（COA） を検索できます。ロット番号・バッチ番号は、製品ラベルに「Lot」または「Batch」に続いて記載されています。
D O Visscher et al.
Journal of biomedical materials research. Part B, Applied biomaterials, 107(5), 1711-1721 (2018-11-02)
The aim of this study was to design and manufacture an easily assembled cartilage implant model for auricular reconstruction. First, the printing accuracy and mechanical properties of 3D-printed poly-ε-caprolactone (PCL) scaffolds with varying porosities were determined to assess overall material
Laura K Zamurs et al.
The Journal of biological chemistry, 290(7), 4272-4281 (2014-12-24)
Bethlem myopathy and Ullrich congenital muscular dystrophy (UCMD) sit at opposite ends of a clinical spectrum caused by mutations in the extracellular matrix protein collagen VI. Bethlem myopathy is relatively mild, and patients remain ambulant in adulthood while many UCMD
Tiziana Triulzi et al.
PloS one, 8(2), e56761-e56761 (2013-02-27)
We recently showed that differential expression of extracellular matrix (ECM) genes delineates four subgroups of breast carcinomas (ECM1, -2, -3- and -4) with different clinical outcome. To further investigate the characteristics of ECM signature and its impact on tumor progression
Te-Cheng Pan et al.
American journal of human genetics, 73(2), 355-369 (2003-07-04)
Recessive mutations in two of the three collagen VI genes, COL6A2 and COL6A3, have recently been shown to cause Ullrich congenital muscular dystrophy (UCMD), a frequently severe disorder characterized by congenital muscle weakness with joint contractures and coexisting distal joint
Russell J Butterfield et al.
Human mutation, 34(11), 1558-1567 (2013-09-17)
Glycine substitutions in the conserved Gly-X-Y motif in the triple helical (TH) domain of collagen VI are the most commonly identified mutations in the collagen VI myopathies including Ullrich congenital muscular dystrophy, Bethlem myopathy, and intermediate (INT) phenotypes. We describe
ライフサイエンス、有機合成、材料科学、クロマトグラフィー、分析など、あらゆる分野の研究に経験のあるメンバーがおります。.
製品に関するお問い合わせはこちら（テクニカルサービス）